55 filings
6-K
CANF
Can-Fite Biopharma Ltd
26 Dec 19
Report of Foreign Private Issuer
7:19am
6-K
CANF
Can-Fite Biopharma Ltd
20 Dec 19
Report of Foreign Private Issuer
4:31pm
6-K
CANF
Can-Fite Biopharma Ltd
12 Dec 19
Current Report of Foreign Issuer
4:32pm
6-K
CANF
Can-Fite Biopharma Ltd
9 Dec 19
Can-Fite Completes 50% Patient Enrollment in its Phase III Psoriasis Trial
8:21am
6-K
CANF
Can-Fite Biopharma Ltd
29 Nov 19
Can-Fite Reports Third Quarter 2019 Financial Results & Provides Clinical Update
7:15am
6-K
4skp3
19 Nov 19
Can-Fite Granted Patents for its Sexual Dysfunction Drug
7:10am
6-K
dmdnddk7e5i
12 Nov 19
Report of Foreign Private Issuer
6:17am
6-K
svsq64s3t29
6 Nov 19
2019 Annual General Meeting of Shareholders
4:42pm
6-K
87hhcbk 1915505q1o7
4 Nov 19
Can-Fite Initiates Compassionate Use Program for Namodenoson in the Treatment of Liver Cancer, Enrolls and Treats Patients
7:13am
6-K
dt0e7u
31 Oct 19
Successful conclusion of an End of Phase II meeting with the FDA
7:12am
6-K
hv2n9
17 Oct 19
Report of Foreign Private Issuer
8:15am
6-K
jbbn74tdbx0 0u
15 Oct 19
Topline results expected Q1 2020
7:00am
6-K
9lu7 xjw656ulektas
10 Oct 19
Can Fite Announces Publication of Namodenoson™ NASH Mechanism of Action in International Journal of Molecular Medicine
7:15am
6-K
glxy62w8zpmocr1s3
7 Oct 19
Current report (foreign)
4:13pm
6-K
1ounqa3
23 Sep 19
Can-Fite Presents New Data on the Treatment of Advanced Liver Cancer with Namodenoson at the ILCA Conference
7:14am
6-K
pqf2lof bk34to5vsm78
17 Sep 19
Current report (foreign)
4:33pm
6-K
0ho iedxreaa81e
13 Sep 19
Current report (foreign)
4:50pm
6-K
18ff nr9v
11 Sep 19
Report of Foreign Private Issuer
5:22pm
6-K
9p0p6mpmdw6zodm8
10 Sep 19
Can-Fite Enters into Strategic Agreement with Univo Pharmaceuticals to Develop Cannabinoid-Based Pharmaceuticals and Assays
6:08am
6-K
l9jy4b4bsb0uyc1lao
6 Sep 19
Report of Foreign Private Issuer
4:18pm